Vitrakvi
Payments companies reported to CMS as associated with Vitrakvi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vitrakvi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vitrakvi
These are the largest totals companies reported as associated with Vitrakvi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Noah Federman | Los Angeles, CA | Pediatric Hematology-Oncology | $45,604.97 |
| Marcia Brose | Philadelphia, PA | Medical Oncology | $26,632.14 |
| Krzysztof Misiukiewicz | New York, NY | Medical Oncology | $26,232.54 |
| Todd Bauer | Nashville, TN | Hematology & Oncology | $20,920.84 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $16,671.84 |
| Eric Vail | West Hollywood, CA | Anatomic Pathology & Clinical Pathology | $16,182.00 |
| Robert Haddad | Boston, MA | Medical Oncology | $15,054.07 |
| Luis Raez | Pembroke Pines, FL | Hematology & Oncology | $13,516.58 |
| Steven Waguespack | Houston, TX | Pediatric Endocrinology | $9,466.44 |
| Jessica Davis | Lafayette, IN | Anatomic Pathology & Clinical Pathology | $9,435.00 |
Prescribed Vitrakvi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.